Paula- For the life of me, I can't find anything like that. Could you be mixing it up with another compound?

Here is an overview-

1. Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1-56.

Citicoline: pharmacological and clinical review, 2006 update.

Secades JJ, Lorenzo JL.

Medical Department, Grupo Ferrer S.A., Barcelona, Spain.

Cytidine 5'-diphosphocholine, CDP-choline, or citicoline is an essential
intermediate in the biosynthetic pathway of structural phospholipids in cell
membranes, particularly phosphatidylcholine. Following administration by both the
oral and parenteral routes, citicoline releases its two main components, cytidine
and choline. Absorption by the oral route is virtually complete, and
bioavailability by the oral route is therefore approximately the same as by the
intravenous route. Once absorbed, citicoline is widely distributed throughout the
body, crosses the blood-brain barrier and reaches the central nervous system
(CNS), where it is incorporated into the membrane and microsomal phospholipid
fraction. Citicoline activates biosynthesis of structural phospholipids of
neuronal membranes, increases brain metabolism, and acts upon the levels of
different neurotransmitters. Thus, citicoline has been experimentally shown to
increase norepinephrine and dopamine levels in the CNS. Owing to these
pharmacological mechanisms, citicoline has a neuroprotective effect in hypoxic
and ischemic conditions, decreasing the volume of ischemic lesion, and also
improves learning and memory performance in animal models of brain aging. In
addition, citicoline has been shown to restore the activity of mitochondrial
ATPase and membrane Na+/K+ATPase, to inhibit activation of certain
phospholipases, and to accelerate reabsorption of cerebral edema in various
experimental models. Citicoline has also been shown to be able to inhibit
mechanisms of apoptosis associated to cerebral ischemia and in certain
neurodegeneration models, and to potentiate neuroplasticity mechanisms.
Citicoline is a safe drug, as shown by the toxicological tests conducted, that
has no significant systemic cholinergic effects and is a well tolerated product.
These pharmacological characteristics and the action mechanisms of citicoline
suggest that this product may be indicated for treatment of cerebral vascular
disease, head trauma (HT) of varying severity, and cognitive disorders of
different causes. In studies conducted in the treatment of patients with HT,
citicoline was able to accelerate recovery from post-traumatic coma and
neurological deficits, achieving an improved final functional outcome, and to
shorten hospital stay in these patients. Citicoline also improved the mnesic and
cognitive disorders seen after HT of minor severity that constitute the so-called
post-concussional syndrome. In the treatment of patients with acute ischemic
cerebral vascular disease, citicoline accelerates recovery of consciousness and
motor deficit, achieves a better final outcome, and facilitates rehabilitation of
these patients. The other major indication of citicoline is for treatment of
senile cognitive impairment, either secondary to degenerative diseases (e.g.
Alzheimer disease) or to chronic cerebral vascular disease. In patients with
chronic cerebral ischemia, citicoline improves scores in cognitive rating scales,
while in patients with senile dementia of the Alzheimer type it stops the course
of disease, and neuroendocrine, neuroimmunomodulatory, and neurophysiological
benefits have been reported. Citicoline has also been shown to be effective in
Parkinson disease, drug addictions, and alcoholism, as well as in amblyopia and
glaucoma. No serious side effects have occurred in any series of patients treated
with citicoline, which attests to the safety of treatment with citicoline.